NCT01386983: Clinical and Economic Outcomes of Patients Utilizing Combination Therapy for Enlarged Prostates: A Henry Ford Database Assessment |
|
|
| Completed | N/A | 332 | NA | 5ARI, Avodart® is a registered trademark of GlaxoSmithKline, Proscar® is a registered trademark of Merck, 5ARI + AB, Hytrin® is a registered trademark of Abbott Laboratories, Flomax® is a registered trademark of Astellas Pharma, Cardura® is a registered trademark of Pfizer Inc, Uroxatral® is a registered trademark of Sanofi-Aventis | GlaxoSmithKline | Prostatic Hyperplasia | 06/10 | 06/10 | | |
NCT01435954: Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy |
|
|
| Completed | N/A | 13551 | NA | Early combination therapy, Flomax® is a registered trademark of Astellas Pharma, Rapaflo® is a registered trademark of Watson Pharmaceuticals, Inc, Proscar® is a registered trademark of Merck, Uroxatral® is a registered trademark of Sanofi-Aventis, Cardura® is a registered trademark of Pfizer Inc, Avodart® is a registered trademark of GlaxoSmithKline, Hytrin® is a registered trademark of Abbott Laboratories, Delayed combination therapy | GlaxoSmithKline | Benign Prostatic Hyperplasia | 03/11 | 03/11 | | |